Global Biologic Medication in COVID-19 Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Biologic Medication in COVID-19 Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
According to China's clinical trials of COVID-19 treatment, the number of chemical drugs accounted for the highest proportion, followed by biological drugs, cell therapy, vaccines, and traditional Chinese medicine. Among the biological drugs, IL-6 related monoclonal antibodies (anti-inflammatory) account for the largest proportion, including tocilizumab and Sarilumab. This report focuses on the investigation and analysis of biologic medication and predicts the future market development of biopharmaceuticals under the influence of COVID-19. Biological drugs are mainly divided into two categoriesneutralizing antibodies and anti-inflammatory drugs. The main subdivisions includeIL-6, C5a, CD147, PD-1 and Interferon (beta-1a), etc.
Biologic Medication in COVID-19 report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Biologic Medication in COVID-19 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from COVID-19 and Influenza are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Biologic Medication in COVID-19 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Biologic Medication in COVID-19 key companies include Roche, Sanofi, Novartis, Merck, Bayer, Shutaishen, Biogen, Regeneron Pharmaceuticals and Vir Biotech, etc. Roche, Sanofi, Novartis are top 3 players and held % share in total in 2022.
Biologic Medication in COVID-19 can be divided into Neutralizing Antibodies and Anti-inflammatory Drugs, etc. Neutralizing Antibodies is the mainstream product in the market, accounting for % share globally in 2022.
Biologic Medication in COVID-19 is widely used in various fields, such as COVID-19, Influenza, Malaria and Others, etc. COVID-19 provides greatest supports to the Biologic Medication in COVID-19 industry development. In 2022, global % share of Biologic Medication in COVID-19 went into COVID-19 filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biologic Medication in COVID-19 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Roche
Sanofi
Novartis
Merck
Bayer
Shutaishen
Biogen
Regeneron Pharmaceuticals
Vir Biotech
Junshi Biosciences
Anke Biotechnology
OncoImmune
Segment by Type
Neutralizing Antibodies
Anti-inflammatory Drugs
COVID-19
Influenza
Malaria
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Biologic Medication in COVID-19 market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Biologic Medication in COVID-19 introduction, etc. Biologic Medication in COVID-19 Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Biologic Medication in COVID-19 market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Biologic Medication in COVID-19 report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Biologic Medication in COVID-19 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from COVID-19 and Influenza are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Biologic Medication in COVID-19 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Biologic Medication in COVID-19 key companies include Roche, Sanofi, Novartis, Merck, Bayer, Shutaishen, Biogen, Regeneron Pharmaceuticals and Vir Biotech, etc. Roche, Sanofi, Novartis are top 3 players and held % share in total in 2022.
Biologic Medication in COVID-19 can be divided into Neutralizing Antibodies and Anti-inflammatory Drugs, etc. Neutralizing Antibodies is the mainstream product in the market, accounting for % share globally in 2022.
Biologic Medication in COVID-19 is widely used in various fields, such as COVID-19, Influenza, Malaria and Others, etc. COVID-19 provides greatest supports to the Biologic Medication in COVID-19 industry development. In 2022, global % share of Biologic Medication in COVID-19 went into COVID-19 filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biologic Medication in COVID-19 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Roche
Sanofi
Novartis
Merck
Bayer
Shutaishen
Biogen
Regeneron Pharmaceuticals
Vir Biotech
Junshi Biosciences
Anke Biotechnology
OncoImmune
Segment by Type
Neutralizing Antibodies
Anti-inflammatory Drugs
Segment by Application
COVID-19
Influenza
Malaria
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Biologic Medication in COVID-19 market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Biologic Medication in COVID-19 introduction, etc. Biologic Medication in COVID-19 Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Biologic Medication in COVID-19 market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices